adMare BioInnovations is Canada's global life sciences venture organization, created in 2019 from the merger of CDRD and NEOMED Institute. It uses scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build and scale Canadian life sciences companies from sea to sea.
75% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 2 prior). Their most common stage is series-a (67% of deals). Average disclosed round size is $64.7M (across 9 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
SW
Sarah Williams
Director, Investments
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kainova Therapeutics | Series B | — | Feb 2026 |
 Epitopea | Series A | $31M | Feb 2025 |
| Epitopea | Series A | $31M | Oct 2024 |
 Abdera Therapeutics Inc. | Series A | $142M | Apr 2023 |
| AAbdera | Series B | $110M | Apr 2023 |
 Abdera Therapeutics | Series B | $110M | Jan 2023 |
 Inversago Pharma | Series C | — | Jan 2023 |
 Domain Therapeutics | Series A | $42M | May 2022 |
| Domain Therapeutics | Series A | $42M | Jan 2022 |
| Kainova Therapeutics | Series A | $42M | Jan 2022 |
| AAbdera | Series A | $32.5M | Jan 2021 |
| Abdera Therapeutics Inc. | Series A | — | Jan 2021 |
Top Co-Investors
Amplitude Ventures5 shared
Viking Global Investors5 shared
Versant Ventures5 shared
3B Future Health Fund4 shared
Panacea Venture4 shared
Viva BioInnovator4 shared
Turenne Capital4 shared
Investissement Québec4 shared
Schroders Capital4 shared
venBio3 shared
Qiming Venture Partners USA3 shared
Fonds de solidarité FTQ3 shared
Omnes Capital3 shared
Cambridge Innovation Capital2 shared
EQT Life Sciences1 shared
Seventure Partners1 shared
Bain Capital Life Sciences1 shared
Foresite Capital1 shared
Johnson & Johnson Innovation1 shared
New Enterprise Associates1 shared
Last updated: 7 October 2026